Gut barrier dysfunction in the ApcMin/+ mouse model of colon cancer cachexia  by Puppa, Melissa J. et al.
Biochimica et Biophysica Acta 1812 (2011) 1601–1606
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad isGut barrier dysfunction in the ApcMin/+ mouse model of colon cancer cachexia
Melissa J. Puppa a, James P. White a, Shuichi Sato a, Mark Cairns a, John W. Baynes a,b, James A. Carson a,b,⁎
a Integrative Muscle Biology Laboratory, Department of Exercise Science, University of South Carolina, Columbia, SC 29208, USA
b Center for Colon Cancer Research, University of South Carolina, Columbia, SC 29208, USA⁎ Corresponding author at: University of South Carolin
ence, Public Health Research Center, Room 405, 921 Ass
USA. Tel.: +1 803 777 0809 (ofﬁce), +1 803 777 0142
E-mail address: carsonj@mailbox.sc.edu (J.A. Carson
0925-4439/$ – see front matter © 2011 Elsevier B.V. All
doi:10.1016/j.bbadis.2011.08.010a b s t r a c ta r t i c l e i n f oArticle history:
Received 11 July 2011
Received in revised form 28 August 2011
Accepted 29 August 2011
Available online 2 September 2011
Keywords:
Cachexia
Colorectal cancer
Endotoxin
Gut barrier dysfunction
Gut permeability
InﬂammationBackground: The ApcMin/+mouse, an animal model of colorectal cancer and cachexia, has a heterologous mu-
tation in the Apc tumor suppressor gene, predisposing the mouse to intestinal and colon tumor development.
This mouse develops intestinal polyps by ~4 weeks of age, and loses body weight gradually between ~14
and ~20 weeks of age. The strengths of this cachexia model derive from several features that mimic human
cancer, including a gradual increase in tumor burden, chronic inﬂammation, and anemia. Little is known
about the role of gut barrier dysfunction and endotoxemia in the development of cancer cachexia. We sought
to determine how gut permeability and resultant endotoxemia change with the progression of cachexia.
Methods: Intestinal gut barrier integrity was assessed by permeability to FITC-dextran (MWav=4000 kDa;
FD4). Plasma glucose and triglycerides were measured by enzymatic assays, IL-6 by enzyme-linked immuno-
sorbent assay, and endotoxin by the limulus amoebocyte assay. Body temperature was measured using a rec-
tal probe. Results: Progression of cachexia was accompanied by development of gut barrier dysfunction
(permeability to FD4), hypertrophy of mesenteric lymph nodes, and an increase in plasma endotoxin concen-
tration. Changes in blood glucose and glucose tolerance, plasma IL-6, triglycerides, and body temperature
were characteristic of endotoxemia. Conclusion: We propose a role for gut barrier dysfunction (GBD) and sub-
sequent endotoxemia in the development of inﬂammation and progression of cachexia in the ApcMin/+ mouse.a, Department of Exercise Sci-
embly St, Columbia, SC 29208,
(Lab); fax: +1 803 777 8422.
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Cachexia, a condition characterized by severe wasting of muscle
and adipose tissue, is a common complication of late-stage cancers,
especially cancers of the gastrointestinal system. It contributes to at
least 20% of deaths from cancer [1]. Cachexia is a metabolic syndrome
associated with underlying illness causing a loss of muscle mass and
fat mass [2]. It is commonly associated with increases in acute
phase proteins and pro-inﬂammatory cytokines in plasma, particular-
ly TNF-∝ and IL-6 [3–5]. The ApcMin/+ mouse is an animal model for
colon cancer research [6,7], which has a mutation in the Apc tumor
suppressor gene. This mouse develops intestinal polyps, beginning
at ~4 weeks of age and begins to develop a progressive cachexia be-
tween 12 and ~20 weeks of age, that culminates in a 20–25% decrease
in body weight. The progression of cachexia is associated with an in-
creased concentration of plasma IL-6, and cachexia is inhibited in an
IL-6 knockout (ApcMin/+ x IL-6−/−) mouse [8] despite the presence
of intestinal and colon tumors. The cachectic response can be restored
by systemic IL-6 over-expression in the ApcMin/+ x IL-6−/− mouse,
while IL-6 over-expression in C57BL/6 mice does not induce cachexia.Thus, IL-6 is necessary, but not sufﬁcient, for induction of cachexia in
mice.
Gut barrier dysfunction (GBD), characterized by breakdown and
leakage of the gut epithelial barrier, leads to systemic inﬂammation
because of entry of bacterial cell wall components (endotoxin), also
known as lipopolysaccharide (LPS), or intact bacteria into the circula-
tion [9]. The resulting inﬂammation is a common problem in critical
care medicine and can lead to multiple organ dysfunction syndrome
[10]. Endotoxemia may be caused by a variety of stresses [11], burn
injury [12], traumatic brain injury [13] or stroke [14], chronic heart
failure [15], pancreatitis [16,17], and even strenuous exercise
[18,19]. The gut receives a substantial fraction of cardiac output and
impairment of the blood supply leads to hypoxia, which may be a
common mediator of the development of gut barrier dysfunction
and endotoxemia. Indeed, hemorrhagic shock [20] followed by resus-
citation (HS/R) induces GBD in mice [21], as measured by increased
intestinal permeability to FITC-dextran and translocation of bacteria
to mesenteric lymph nodes. Like the ApcMin/+ model, development
of cachexia in the HS/R model, GBD is dependent on increased circu-
lating IL-6 concentration; IL-6 knock-out mice do not develop GBD
after HS/R [21]. The observation that IL-6 is required, but not sufﬁ-
cient, for development of cachexia in both the ApcMin/+ [8] and HS/R
models [21], and that GBD is implicated in the pathogenesis of ca-
chexia in the HS/R model led us to investigate the possible role of
GBD and endotoxemia in development and progression of cachexia
in the ApcMin/+ mouse.
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2.1. Animals
C57BL/6 and ApcMin/+ mice were originally purchased from Jackson
Laboratories (Bar Harbor, ME), and breeding was continued at the Uni-
versity of South Carolina's Animal Resource Facility, as previously de-
scribed [22]. The room was maintained on a 12:12 light:dark cycle
with the light period starting at 0700. Mice were provided standard ro-
dent chow (Harlan Teklad Rodent Diet, #8604, Madison,WI) andwater
ad libitum. Body weights were measured weekly. Male mice (n=5–10
animals) were used in each group for all experiments. All animal exper-
imentation was approved by the University of South Carolina's Institu-
tional Animal Care and Use Committee.
2.2. Tissue sampling and physiological measurements
Mice were anesthetized with a ketamine/xylazine/acepromazine
cocktail (1.4 ml/kg body weight), and tissues were removed, weighed
and frozen at −80 °C until further analysis. Blood samples were col-
lected in heparinized capillary tubes from the retroorbital sinus
under brief isoﬂurane anesthesia.
Rectal temperature was measured using a rectal probe designed
for mice (Thermalert TH-5, Physitemp, Clifton, NJ). Temperature
was measured at the same time of day bi-weekly for the duration of
the study.
Gut barrier integrity was assessed by permeability to FITC-dextran
(MWav=4000; FD4). The FD4 was administered by gavage
(600 mg/kg BW; 125 mg/ml of phosphate-buffered saline) to fasted
mice. Plasma was sampled prior to the gavage and 1 h after the proce-
dure and measured for ﬂuorescence, as described by Yang et al. [21].
2.3. Biochemical assays
Plasma endotoxin was measured by a chromogenic Limulus
Amoebocyte Lysate (LAL) assay (product no. HIT302; Hycult Biotech,
Plymouth Meeting, PA). Plasma triglycerides were measured using a
colorimetric assay (Thermo Scientiﬁc), and IL-6 using a mouse IL-6
ELISA (Invitrogen), performed according to manufacturer's instruc-
tions. An intraperitoneal glucose tolerance test was performed after
an overnight fast by injecting a 20% glucose solution (2 g glucose/kg
body weight). Glucose was measured at 0, 15, 30, 60, and 90 min
after injection using a Bayer (Mishawaka, IN) Ascencia Contour
glucometer.
2.4. IL-6 over-expression
At 12 weeks of age mice were electroporated with either an empty
vector (vector) or an IL-6 plasmid (IL-6), as previously described [8].
The IL-6 plasmid, driven by the cytomegalovirus (CMV) promoter,
was used to increase endogenous IL-6 production in the mice. The
micewere anesthetizedwith amixture of isoﬂurane and oxygen during
the procedure.While unconscious the right legwas shaved and cleaned
with alcohol. A small incisionwasmade over the quadricepsmuscle and
50 μ of either control vector or IL-6 plasmid was injected into the mus-
cle. To promote uptake of the plasmid into the myoﬁbers a series of
eight 100 V pulses lasting 50 ms each was used on the quadricepsmus-
cle. Each pulse consisted of a 1 s train of square bipolar pulses delivered
every other second. Each train consists of 1000 pulses of 200 μs in
length. The skin was then closed with a wound clip. Mice were then
sacriﬁced at 14 weeks of age.
2.5. Statistical analysis
Repeated measures ANOVA was used to examine changes in body
weight and rectal temperature over time in mice categorized by stageof cachexia. One-way ANOVAs or independent t-tests were used to
determine signiﬁcance for all other variables. Post-hoc analyses
were performed with Student-Newman–Keuls methods. Signiﬁcance
was set at pb0.05.
3. Results
3.1. Progression of cachexia ApcMin/+ mice
ApcMin/+ mice develop tumors by ~4 weeks of age, but continue to
grow in parallel with C57BL/6 mice until ~12 weeks, when they begin
to lose bodyweight (Fig. 1A). By 20 weeks of age, ApcMin/+mice typical-
ly lose 20–25% of body mass, compared to either their maximal weight
or the C57BL/6 control mice (Fig. 1A). Polyp number reaches a plateau
at ~12 weeks (Fig. 1B). Tumor size continues to increase during the
12th–20th week, as the ApcMin/+ mice develop cachexia; eventual-
ly ~80% of the polyps grow to 2 mm or greater in diameter (Fig. 1C).
The weight loss and increase in tumor size are accompanied by a signiﬁ-
cant increase in plasma IL-6 concentration (Fig. 1D). As previously
reported, IL-6, a marker of inﬂammation, increases with severity of ca-
chexia and age in the ApcMin/+ mice [23], consistent with a strong in-
ﬂammatory response during cachexia [8,24].
3.2. Gut barrier permeability increases during cachexia
The integrity of the gut barrier can be assessed by measuring its
permeability to neutral hydrophilic polymers, such as FD4. Gut barrier
permeability was negligible in C57BL/6 controls throughout 20 weeks
of the study, while permeability to FD4 begins to increase in ApcMin/+
mouse, starting at 12–14 weeks of age (Fig. 2A), corresponding to the
time of onset of cachexia (Fig. 1A). By 20 weeks of age, which corre-
sponds with the severely catechetic condition, there was a signiﬁcant
increase in gut permeability in ApcMin/+mice. There was a strong corre-
lation between plasma IL-6 and intestinal permeability (r2=0.55,
pb0.001) in untreated ApcMin/+mice at 20 weeks (Fig. 2C) and a signiﬁ-
cant correlation between the number of large polyps (N2 mm) and in-
testinal permeability (r2=0.38; p=0.003). Intestinal permeability
also increased 3-fold, compared to vector-injected controls, when IL-6
was over-expressed inApcMin/+mice for 2 weeks at the onset of cachexia
(12 weeks of age) (Fig. 2B), consistent with a role for IL-6 in develop-
ment of GBD. There was also ameasurable increase in FD4 permeability
in the vector-injected mice, compared to C57Bl/6 controls, at 14 weeks,
which is attributable to the normal increase in intestinal permeability in
ApcMin/+ at this time.
3.3. Endotoxemia develops during cachexia
Trace levels of endotoxin are detectable in plasma of control mice,
and similar levels were detected in pre-cachectic ApcMin/+ mice at
12 weeks of age. However, endotoxin increased by ~5-fold in severely
cachectic animals at 19 weeks of age (Fig. 3), corresponding to the in-
crease in gut permeability to FD4. The bar on the right in this ﬁgure
represents plasma endotoxin concentration at 12 h after intraperito-
neal injection of 250 μg LPS into a C57BL/6 mouse at 20 weeks of
age. Intestinal lymph nodes were also signiﬁcantly enlarged between
12 and 14 weeks of age and remained enlarged through 20 weeks
(Fig. 4), possibly as a consequence of LPS or bacterial penetration
into the mesenteric lymphatic system.
3.4. Hypothermia develops during cachexia
Acute injection of LPS into normal mice induces hypothermia [25],
possibly as a protective mechanism to limit tissue damage from the
inﬂammatory response [26]. As shown in Fig. 5, ApcMin/+ mice also
experience a gradual decline in body temperature during develop-
ment of cachexia. Intraperitoneal injection of a bolus of 250 μg
Fig. 1. Changes in body weight and tumor distribution in ApcMin/+ mice. A) Body weight was measured weekly, C57BL/6 (●, N=10) and ApcMin/+ (○, N=9) mice. (B and C) In-
testines were evaluated in mice that were sacriﬁced at 12, 14 and 20 weeks of age. Polyps were counted and categorized by diameter. D) Changes in IL-6 concentration during pro-
gression of cachexia. Data are expressed as means±SE. *pb0.05 indicates signiﬁcant difference from controls.
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temperature to 29.9±0.2 °C at 12 h (n=2). Although their tempera-
tures were comparable, the LPS-injected control animals were more
lethargic than ApcMin/+ mice at 16–20 weeks of age, consistent with
lower-level, chronic exposure to endotoxin in the cachectic animals
(Fig. 3).
3.5. Changes in lipemia and insulin resistance during development of
cachexia
ApcMin/+ mice developed severe hypertriglyceridemia, which is
maintained during the progression of cachexia (Fig. 6). Although fasting
blood glucosewas not signiﬁcantly altered, glucose tolerance tests were
abnormal in cachectic animals, based on delayed clearance of glucose at
90 min and the 29% increase (p=0.05) in Area-Under-the Curve (AUC)
for the glucose tolerance test (Fig. 7). Alterations in lipemia and insulin
resistance are commonly seen in cachexia [27]. These changes are in-
dicative of major shifts in energymetabolism in response to inﬂamma-
tion in cachectic animals and, as discussed below, are also common
sequelae of endotoxemia.
4. Discussion
4.1. Role of endotoxemia in cachexia
Cachexia is a challenging complication of end-stage cancer, affecting
a patient's overall health and vitality, ability to withstand infection, and
to respond to chemotherapy or other interventions. Dealing aggressive-
ly with cachexia is critical for increasing patient survival. While therehas been considerable focus on the distal consequences of cachexia,
i.e. themechanisms involved in adipose andmuscle wasting, it is equal-
ly, if notmore, important from a clinical perspective to elucidate the pri-
mary, proximal mechanisms initiating cachexia. The ApcMin/+ mouse is
an acceptedmodel of colorectal cancer cachexia. In this model themice
grow at a normal rate until approximately 12 weeks when intestinal
polyps reach a plateau in numbers. After this the polyps grow in size
without increasing in number and the animals begin to lose weight
gradually until 16 weeks of age when there is a more severe decrease
in body weight. These data suggest that it is not just the presence of
the polyps that leads to cachexia, but the size of the polyps contributes
to the degree of weight loss.
In the present study, we have developed both direct and indirect
evidence supporting a role for endotoxemia in development of ca-
chexia in the ApcMin/+ mouse model of colon cancer. The direct evi-
dence is the detection of GBD (increased FD4 permeability) and the
appearance of endotoxin in the circulation during the progression of
cachexia. The plasma endotoxin concentration, while only modestly
(~5-fold) increased, represents a steady state balance between its
rate of entry into the circulation through the mesenteric lymph
ducts and its rate of clearance from plasma in reticuloendothelial
and other organs. The enlargement of mesenteric lymph nodes may
be consistent with entry of endotoxin (or intact bacteria) through
the intestinal lymphatic system [28,29]. Acute intravenous adminis-
tration of endotoxin also increases intestinal permeability in rodents
[30,31] and humans [32], suggesting a possible ampliﬁcation loop in
which gastrointestinal damage promotes endotoxin leakage, which
then promotes an escalating cycle of endotoxin exposure and intesti-
nal leakage. Indirect evidence for endotoxemia in cachectic mice
Fig. 2. Gut permeability (barrier dysfunction) increases during development of cachexia
in ApcMin/+ mice. A) Measurements were taken at 12 (n=8), 14 (n=7) and 20
(n=10) weeks of age. B) Measurements were taken before and after 2 weeks of IL-6
over-expression (n=5–6 per group). C) IL-6 correlates with increases in gut permeability
in mice measured at 12, 14, and 20 weeks of age. Serum ﬂuorescein dextran concentra-
tions (λex=485; λem=535 nm) were measured at 1 h after gavage. Data are expressed
asmeans±SE. **pb0.05, indicates signiﬁcant difference fromother groups; *pb0.05 com-
pared with 14 week BL-6 Vector; # pb0.05 compared with 14 week BL-6 IL-6; ND=not
detected.
Fig. 3. Plasma endotoxin concentration increases during development of cachexia in
ApcMin/+ mice. N=7–9 per group. Right hand bar represents plasma endotoxin concen-
tration in C57BL/6 mice at 12 h after intraperitoneal injection of 250 μg of endotoxin
(N=2). Data are means±SE. * pb0.05. vs. all other groups.
Fig. 4.Mesenteric lymph nodes are enlarged in ApcMin/+ compared to C57BL/6mice at 12,
14, and 20 weeks of age. Mesenteric lymph nodes were taken in C57BL/6 and ApcMin/+
mice at 12 (n=8/8), 14 (n=8/8) and 20 (n=9/6) weeks of age. Data are expressed as
means±SE. bpb .05 compared to 12 week ApcMin/+.
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endotoxemia, including hypothermia [25,26,33], hypertriglyceridemia
[34,35], and insulin resistance [36,37], as well as the chronic inﬂamma-
tory state characterized by increased plasma concentrations of IL-6 [8].
However, the increase in the inﬂammatory biomarker IL-6 alone is not
sufﬁcient to cause these changes since IL-6 injection does not induce ca-
chexia in control C57Bl/6 mice [8] or GBD (increased FD4 permeability)
in ApcMin/+ mice (Fig. 2B).4.2. Source of GBD
While we have documented increases in GBD and endotoxemia in
the ApcMin/+ mouse, we do not have sufﬁcient information at this
stage to identify the primary cause of GBD. Tumor growth or macro-
phage inﬁltration and inﬂammation in the intestinal wall may affect
gastrointestinal permeability, either locally or throughout the intes-
tine through alterations in epithelial tight junctions. Soler et al.
showed that in humans and rats tight junction permeability is in-
creased in the region surrounding intestinal tumors [38]. Tight junc-
tion protein such as ZO-1 and occludin are also decreased in tumor
Fig. 5. Decrease in body temperature with development of cachexia in ApcMin/+ mice.
Mean rectal temperature is shown for C57BL/6 (●, N=10) and ApcMin/+ (○, N=9)
mice, C57BL/6 mice at 12 h after intraperitoneal injection of 250 μg of endotoxin (▲,
N=2). Data are expressed as means±SE. *pb .05 indicates signiﬁcant difference
from controls.
Fig. 7. Insulin resistance increases during development of cachexia in ApcMin/+ mice.
Glucose (2.0 g/kg of body weight) was injected intraperitoneally. Glucose was mea-
sured at 0, 15, 30, 60 and 90 min. Results are means±SE, N=6.
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tight junction proteins would increase permeability and allow pas-
sage of large molecules such as LPS into the lymphatic circulation.
Changes in mucin secretion andmucin proﬁles in gastrointestinal car-
cinomas [40,41] may also contribute to increased gut permeability. It
is also possible that, as observed in HS/R [21] and acute pancreatitis
[42], decreased splanchnic blood ﬂow and resultant hypoxia might
contribute to GBD. Hypoxia may also develop as a result of severe
anemia, which may also cause hypoxia. We have reported previously
[43] that blood hemoglobin concentration and red cell hemoglobin
content fall by ~50% during the rapid phase of weight loss (16–
20 weeks) in the ApcMin/+ mouse, suggesting that decreases in oxygen
transport to the intestine may underlie the development of hypoxia.
All of thesemechanismsmay be linked through hypoxia-inducedmuco-
sal damage and subsequent lifting of the intestinal epithelia. This lifting
of the epithelia disrupts junctional proteins and leads to increased gut
permeability [44].
4.3. Role of inﬂammation in GBD
Increases in circulating IL-6 are necessary for development of ca-
chexia in the ApcMin/+mouse [8]. We show here that plasma IL-6 con-
centration also increases in concert with changes in intestinal
permeability, and that tumor size also correlates with increased intes-
tinal permeability. The strong correlations between permeability toFig. 6. Plasma triglyceride concentration increases during development of cachexia in
the ApcMin/+ mouse. Plasma triglyceride concentration was measured in the same ani-
mals over time, N=7–9. Data are expressed as means±SE. bpb .05 indicates signiﬁcant
difference from controls and ApcMin/+ at 9 weeks.FD4, tumor size, and plasma IL-6 in the ApcMin/+ mouse, as well as
the increase in permeability following IL-6 overexpression, suggest
that GBD and endotoxemia are associated with, and perhaps the im-
mediate cause of, both inﬂammation and cachexia. While more
work is required to deﬁne the mechanisms underlying the increase
in gut permeability, the general observations regarding compromised
barrier function in this model of colon cancer may also apply to other
cancers with a high frequency of cachexia, such as pancreatic or lung
cancer.5. Conclusion
Effective treatment of cachexia would have a signiﬁcant impact on
survival of patients with colorectal and other cancers. We show data
to support that gut barrier dysfunction and endotoxemia develop
concurrently with a surge in IL-6 and tumor growth present during
cachexia. While our studies on cachexia are limited thus far to the
ApcMin/+ mouse model, our observations suggest that endotoxemia
should be evaluated in clinical studies of cachectic patients, especially
those with gastrointestinal cancers. If endotoxemia or GBD is a com-
mon feature of cachexia, then efforts to limit gastrointestinal toxicity
and/or preserve the integrity of the gut epithelial barrier during therapy
may have a signiﬁcant impact on cancer morbidity and mortality.Acknowledgements
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